Evidence map›Paper›PMID 40532127›Full record

ArticleJCO clinical cancer informatics2025

Artificial Intelligence-Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy.

Magdalena Fay, Ross S Liao, Zaeem M Lone, Chandana A Reddy, Hassan Muhammad, Chensu Xie, Parag Jain, Wei Huang, Hirak S Basu, Sujit S Nair and 9 more

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Magdalena FayCleveland Clinic Lerner College of Medicine, Cleveland, OH.ORCID 0000-0002-6086-931X
Ross S LiaoGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-7977-3767
Zaeem M LoneGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-1394-1948
Chandana A ReddyDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-3832-8744
Hassan MuhammadPathomIQ Inc, Cupertino, CA.
Chensu XiePathomIQ Inc, Cupertino, CA.
Parag JainPathomIQ Inc, Cupertino, CA.
Wei HuangPathomIQ Inc, Cupertino, CA.ORCID 0000-0003-0813-4188
Hirak S BasuPathomIQ Inc, Cupertino, CA.ORCID 0000-0001-7733-8008
Sujit S NairTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-3039-523X
Dimple ChakravartyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Sean R WilliamsonRobert J. Tomisch Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-3898-1460
Shilpa GuptaDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-8775-503X
Christopher WeightGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Rajat RoyPathomIQ Inc, Cupertino, CA.
George WildingPathomIQ Inc, Cupertino, CA.ORCID 0009-0000-5775-5293
Ashutosh K TewariTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-1783-0698
Omar Y MianHuman Biology and Radiation Oncology, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-8133-8120

Funding

Artificial intelligence enabled Stroma-Weighted Automated Grading system to improve risk stratification in Black MenR01CA290438 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Gustavo Enrique Ayala, Surinder K. Batra · 2025 to 2026
$1.4M
NCI NIH HHS R01 CA290438
6 · The paper itself

Abstract

purposeArtificial intelligence (AI) tools that identify pathologic features from digitized whole-slide images (WSIs) of prostate cancer (CaP) generate data to predict outcomes. The objective of this study was to evaluate the clinical validity of an AI-enabled prognostic test, PATHOMIQ_PRAD, using a clinical cohort from the Cleveland Clinic.

methodsWe conducted a retrospective analysis of PATHOMIQ_PRAD using CaP WSIs from patients who underwent radical prostatectomy (RP) between 2009 and 2022 and did not receive adjuvant therapy. Patients also had Decipher genomic testing available. WSIs were deidentified, anonymized, and outcomes were blinded. Patients were stratified into high-risk and low-risk categories on the basis of predetermined thresholds for PATHOMIQ_PRAD scores (0.45 for biochemical recurrence [BCR] and 0.55 for distant metastasis [DM]).

resultsThe study included 344 patients who underwent RP with a median follow-up of 4.3 years. Both PathomIQ and Decipher scores were associated with rates of biochemical recurrence-free survival (BCRFS; PathomIQ score >0.45

conclusionThese findings independently validate PATHOMIQ_PRAD as a reliable predictor of clinical risk in the postprostatectomy setting. PATHOMIQ_PRAD therefore merits prospective evaluation as a risk stratification tool to select patients for adjuvant or early salvage interventions.

Indexed as

Artificial IntelligenceProstatectomyProstatic NeoplasmsAgedFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingPrognosisRetrospective StudiesRisk Assessment

Identifiers

PMID40532127
PMCPMC12184973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.